

THRU ONLINE FILING

June 12, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Sub: Press Release / Media Release

Dear Sir,

We are enclosing herewith the Press Release issued by the Company w.r.t licensing agreement granting Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialization of multiple monoclonal antibody products targeting oncology and inflammatory diseases.

Thanking you.

Yours faithfully
For Ipca Laboratories Limited

Harish P. Kamath
Corporate Counsel & Company Secretary
ACS 6792

Encl: a/a

Ipca Laboratories Ltd.
www.ipca.com

Ipca Laboratories, Mumbai and Bhami's Research Laboratory Announce Global Licensing Collaboration for Novel Subcutaneous Biologics Delivery Technology of Multiple Monoclonal Antibodies

Mumbai, IN [June, 12th 2026] **Ipca Laboratories Ltd.** (Ipca) (NSE: IPCALAB) and Bhami's Research Laboratory (BRL) today announced a definitive global licensing agreement granting Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialization of multiple monoclonal antibody products targeting oncology and inflammatory diseases.

Executive quotes

Pranay Godha, MD & CEO, Ipca Laboratories

“By pairing Ipca’s established science with BRL’s Novel Formulation Platform, we’re accelerating developing affordable biologics for people battling cancer and autoimmune disease worldwide.”

Surya Pai, CEO & Co-Founder, BRL

“We are delighted to be expanding the reach of our novel, proprietary, patented subcutaneous protein delivery platform technology through this exciting partnership with Ipca to develop differentiated biologics for the global market. This strategic partnership is designed to make patient care convenient, affordable and safe” said Dr Suryakanth M Pai, Co-founder and CEO of BRL.”

Akhil Shah, Director & CEO, WeTranslate

“WeTranslate was founded with a simple belief—that world-class innovation deserves world-class commercialization pathways. BRL has built a differentiated formulation technology platform, and Ipca brings the scale, expertise, and global reach required to unlock its full potential. We are delighted to support this collaboration and look forward to seeing its impact on the future of biologic drug delivery.”

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Deal Snapshot

Element	Details
License territory	Worldwide
Scope	Proof Of concept (POC) development and Formulation Development by BRL and Further Research and Development, Clinical Trials, Commercial Manufacturing & Launch by Ipca
Licensing Fee	BRL will receive defined milestone fee pertaining to the Technology Transfer
Royalty	BRL will receive Royalty on net sales upon commercialization of the product

About Ipca Laboratories Ltd., Mumbai, India

Established in 1949, Ipca is a pharmaceutical company with a strong thrust on exports which now account for nearly 50% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients. For more than 70 years, Ipca has been a crucial healthcare partner in over 120 countries across the globe.

Today, Ipca is one of the world's largest manufacturers and suppliers of over a dozen APIs. These APIs are produced at manufacturing facilities approved by the world's most discerning drug regulatory authorities like US-FDA, EDQM-Europe, PMDA Japan and WHO-Geneva, among others.

In addition, Ipca is making significant strides in developing in-house capabilities in biosimilars/biologicals, with a specific emphasis on the development and commercialization of anti-cancer and anti-inflammatory monoclonal antibodies. Ipca has established a world class bio-manufacturing facility in Pithampur (MP) and state of the art R&D facility in Mumbai (MH) for its biosimilar development. These efforts are not just a continuation of the existing work, but rather a bold step forward into vital areas of healthcare.

This initiative is decidedly comprehensive, as Ipca strategically targets various key markets, including the USA, UK, EU, JP, CA, India, and the rest of the world (ROW). These advancements in the new SubQ formulation development will enhance Ipca's product portfolio and substantially address significant healthcare needs across these regions, improving the quality of life for countless individuals.

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

About Bhami Research Laboratory , Mangalore, India

Bhami Research Laboratory Pvt. Ltd. (BRL) is a one of a kind , 12-year-old biotech founded with a mission to reimagine patient friendly, affordable biologics drug delivery. BRL is headquartered in Mangalore, India, with core expertise in protein and peptide drug delivery.

BRL is focused on patient friendly delivery of biologic therapeutics through its proprietary high concentration subcutaneous protein delivery and exciting oral biologics delivery platform technologies. Both these innovations are high value propositions for Global and Indian Biopharma. BRL typically follows a licensing model wherein it out-licenses the technology on a molecule specific basis.

About WeTranslate, Mumbai, India

WeTranslate is a life sciences business development and technology partnering firm focused on licensing and strategic collaborations within the biopharmaceutical industry.

Serving as BRL's strategic licensing partner, WeTranslate supported the development and execution of the collaboration between BRL and Ipca Laboratories.

Media contacts

WeTranslate: Akhil Shah: akhil.shah@wetranslate.science

BRL: suryapai@bhamilab.com, For more information, www.bhamilab.com.

Ipca: Corporate Communications | corpcomm@ipca.com